The relationship between dosimetric factors, side effects, and survival in patients with non-small cell lung cancer treated with definitive radiotherapy

Simple item page
dc.contributor.authorOkumuş, Dilruba
dc.contributor.buuauthorSarıhan, Sureyya
dc.contributor.buuauthorGözcü, Sema
dc.contributor.buuauthorSığırlı, Deniz
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.tr_TR
dc.contributor.researcheridAAH-4970-2021tr_TR
dc.contributor.researcheridAAA-7472-2021tr_TR
dc.contributor.scopusid56404684500tr_TR
dc.contributor.scopusid54381741300tr_TR
dc.contributor.scopusid24482063400tr_TR
dc.date.accessioned2023-01-19T11:20:56Z
dc.date.available2023-01-19T11:20:56Z
dc.date.issued2017-02-06
dc.description.abstractThe patients with non small cell lung cancer (NSCLC) treated with definitive conformal radiotherapy (RT) were evaluated in terms of side effects and survival. Normal tissue complication probability (NTCP) was calculated for 68 patients treated between 2009 and 2012. Clinical and dosimetric factors were analyzed. The median dose of 63 Gy (range: 54 to 70 Gy) was given with conformal RT with blocks (n = 37), 3-dimensional conformal RT (3DCRT) (n =11), or intensity-modulated RT (IMRT) (n = 20). Acute grade 1 to 2 radiation pneumonitis (RP) was seen in 13% of the patients. No significant relationship was found between RP and treatment and dosimetric factors (p > 0.05). There was a positive correlation between median "mean lung dose" (MLD) (17 Gy), lung V30 (20.5%), and NTCP (14%) (p < 0.001). Median and 2-year overall survival (OS) and progression-free survival (PFS) were 27 and 18 months and 51% and 42%, respectively. In univariate analysis, significant dose range for survival was found between 59.4 and 63 Gy (p < 0.01). In multivariate analysis, response (p = 0.001), fraction dose of 1.8 Gy (p = 0.002), MLD <18 Gy (p = 0.04) for OS and response (p < 0.001), total dose > 59.4 Gy (p = 0.01), and tumor biologically effective dose (BED)3(Gy) 5100.8 (p = 0.01) for PFS were found to be favorable factors. In our study, we found a linear correlation between NTCP and MLD for RP risk estimation in patients with NSCLC. Therapeutic dose range where MLD can be kept under 20 Gy with significant survival benefit was found between 59.4 and 63 Gy. Increased therapeutic efficacy will be possible using risk-adaptive RT techniques.en_US
dc.identifier.citationOkumuş, D. vd. (2017). ''The relationship between dosimetric factors, side effects, and survival in patients with non-small cell lung cancer treated with definitive radiotherapy''. Medical Dosimetry, 42(3), 169-176.en_US
dc.identifier.endpage176tr_TR
dc.identifier.issn0958-3947
dc.identifier.issue3tr_TR
dc.identifier.pubmed28506589tr_TR
dc.identifier.scopus2-s2.0-85018915827tr_TR
dc.identifier.startpage169tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.meddos.2017.02.002
dc.identifier.urihttps://www.sciencedirect.com/science/article/abs/pii/S0958394717300201
dc.identifier.uri1873-4022
dc.identifier.urihttp://hdl.handle.net/11452/30566
dc.identifier.volume42tr_TR
dc.identifier.wos000411424200002tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalMedical Dosimetryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectRadiology, nuclear medicine & medical imagingen_US
dc.subjectDefinitive conformal radiotherapyen_US
dc.subjectDosimetric factorsen_US
dc.subjectRadiation pneumonitisen_US
dc.subjectSide effectsen_US
dc.subjectSurvivalen_US
dc.subjectDose-volume histogramen_US
dc.subjectIntensity-modulated radiotherapyen_US
dc.subjectRadiation pneumonitisen_US
dc.subjectParametersen_US
dc.subjectEscalationen_US
dc.subjectToxicityen_US
dc.subjectRisken_US
dc.subject.emtreeCarboplatinen_US
dc.subject.emtreeCisplatinen_US
dc.subject.emtreeDocetaxelen_US
dc.subject.emtreePaclitaxelen_US
dc.subject.emtreeAdrenal insufficiencyen_US
dc.subject.emtreeAdrenal metastasisen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBone metastasisen_US
dc.subject.emtreeBrain metastasisen_US
dc.subject.emtreeCancer radiotherapyen_US
dc.subject.emtreeCancer survivalen_US
dc.subject.emtreeClinical effectivenessen_US
dc.subject.emtreeConformal radiotherapyen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeDosimetryen_US
dc.subject.emtreeEffective dose (radiation)en_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHerpes zosteren_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeIntensity modulated radiation therapyen_US
dc.subject.emtreeLeukopeniaen_US
dc.subject.emtreeliver metastasisen_US
dc.subject.emtreeLung fibrosisen_US
dc.subject.emtreeLung volumeen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMedian survival timeen_US
dc.subject.emtreeNon small cell lung canceren_US
dc.subject.emtreeOverall survivalen_US
dc.subject.emtreePericardial effusionen_US
dc.subject.emtreePericardiocentesisen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProgression free survivalen_US
dc.subject.emtreeRadiation doseen_US
dc.subject.emtreeRadiation dose distributionen_US
dc.subject.emtreeRadiation hazarden_US
dc.subject.emtreeRadiation pneumoniaen_US
dc.subject.emtreeRadiation safetyen_US
dc.subject.emtreeRadiological parametersen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.emtreeSmokingen_US
dc.subject.emtreeSoft tissue metastasisen_US
dc.subject.emtreeSquamous cell lung carcinomaen_US
dc.subject.emtreeStandardized uptake valueen_US
dc.subject.emtreeTreatment responseen_US
dc.subject.emtreeEpidemiologyen_US
dc.subject.emtreeLung tumoren_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreeMortalityen_US
dc.subject.emtreeNon small cell lung canceren_US
dc.subject.emtreeRadiotherapy dosageen_US
dc.subject.emtreeStatistics and numerical dataen_US
dc.subject.emtreeVery elderlyen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAged, 80 and overen_US
dc.subject.meshCarcinoma, non-small-cell lungen_US
dc.subject.meshFemaleen_US
dc.subject.meshHumansen_US
dc.subject.meshLung neoplasmsen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshRadiotherapy dosageen_US
dc.subject.meshRadiotherapy, intensity-modulateden_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshTurkeyen_US
dc.subject.scopusNon-Small Cell Lung Carcinoma; Esophagitis; Lung Injuryen_US
dc.subject.wosOncologyen_US
dc.subject.wosRadiology, nuclear medicine & medical imagingen_US
dc.titleThe relationship between dosimetric factors, side effects, and survival in patients with non-small cell lung cancer treated with definitive radiotherapyen_US
dc.typeArticle
dc.wos.quartileQ4en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus